We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
INHIBITION OF THE MITOGEN ACTIVATED PROTEIN KINASE (MAPK) IN THE INFLAMMATORY PAIN LIKE STATE USING SB 203580 AND PD 98059 IN MICE.
- Authors
Zulkarnain, Bambang Subakti; Khotib, Junaidi
- Abstract
The therapeutic management of pain related inflammation is difficult to handle. The inflammatory process is mediated through the mitogen-activated protein kinase (MAPK) signal transduction pathway. Inhibition of this signal with specific inhibitors of the p38 and Erk 1/2 MAPK pathway i.e. SB 203580 and PD 98059 has been reported. This study was aimed to assess the effectiveness of those specific inhibitors for inflammatory pain management in mice. Inflammatory model was developed by intraplantar injection of Complete Freud's Adjuvant (CFA). Intrathecally administered of SB 203580 and PD 98059 was injected once a day for 7 consecutive days at dose of 0.1, 1.0 and 5.0 mmol that was started from day 7 to day 13 after CFA injection. Hyperalgesia was measured on day 0,1,3,5,7,8,10,12, and 14 following CFA injection. At dose of 5.0 nmol, PD 98059 increased mice's latency time to heat stimulation compared with placebo (F(3.26)=6.881; p=0.001). Also, SB 203580 at dose of 0.1, 1.0 and 5.0 showed similar results compared with placebo (F(3.25)=4.394; p=0.002, p=0.001 and p=0.039 for doses 0.1, 1.0 and 5.0 nmol respectively ). MAPK inhibitors could have a place of therapy in the inflammatory pain like state due to its effectiveness in decreasing hyperalgesia.
- Subjects
MITOGEN-activated protein kinases; INFLAMMATION; THERAPEUTICS; LABORATORY mice; INJECTIONS; PLACEBOS
- Publication
Folia Medica Indonesiana, 2010, Vol 46, Issue 3, p192
- ISSN
0303-7932
- Publication type
Article